41st week of 2020 patent applcation highlights part 10 |
Patent application number | Title | Published |
20200315983 | TISSUE THICKNESS COMPENSATOR CONFIGURED TO REDISTRIBUTE COMPRESSIVE FORCES - A tissue thickness compensator may generally comprise a compressible core comprising a plurality of movable particles, and a wrap surrounding the compressible core. The plurality of movable particles may comprise at least one medicament. A tissue thickness compensator may generally comprise a compressible core comprising a plurality of crushable particles, and a wrap surrounding the compressible core. The plurality of crushable particles may comprise at least one medicament. The compressible core may comprise a material selected from a group consisting of a biocompatible material. The wrap may comprise a material selected from a group consisting of a biocompatible material. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described. | 2020-10-08 |
20200315984 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent. | 2020-10-08 |
20200315985 | UNIFORM FILMS FOR RAPID-DISSOLVE DOSAGE FORM INCORPORATING ANTI-TACKING COMPOSITIONS - The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent. | 2020-10-08 |
20200315986 | CANNABINOID AND MENTHOL GEL COMPOSITIONS, PATCHES AND METHODS - The present disclosure relates to compositions methods of use and methods of manufacturing, hydrous hydrogel compositions useful as topical oral analgesics including cannabinoids and menthol where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid. | 2020-10-08 |
20200315987 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE POLYMER - The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone polymer. | 2020-10-08 |
20200315988 | CANNABINOID AND MENTHOL GUM AND LOZENGE COMPOSITIONS AND METHODS - The present disclosure relates to chewing gum or lozenge with cannabinoids and menthol including a liquid-filled chewing gum or lozenge with a chewing gum base shell or lozenge candy shell enclosing an internal void therein and a liquid filling in the void, the liquid-filled chewing gum or lozenge including cannabinoids and menthol. The menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid. | 2020-10-08 |
20200315989 | COMPOSITION COMPRISING FARNESOL AND USE THEREOF - A method of increasing PGC-1α gene expression, decreasing PARIS gene expression, or promoting farnesylation of PARIS in a mammalian cell, the method comprising administering an effective amount of farnesol, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell; and related methods and compositions. | 2020-10-08 |
20200315990 | USE OF A LIGNIN FRACTION AS A HUMAN AND ANIMAL FOOD SUPPLEMENT INGREDIENT - The use of a lignin fraction as a human and animal food supplement ingredient, as well as food supplements comprising the same, are disclosed. | 2020-10-08 |
20200315991 | PARENTERAL TREATMENTS INVOLVING AMINOADAMANTANE DERIVATIVES - A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof. | 2020-10-08 |
20200315992 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation. | 2020-10-08 |
20200315993 | COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES - There is herein provided pharmaceutical formulations and kits-of-parts comprising a β | 2020-10-08 |
20200315994 | EXTENDED RELEASE LIQUID COMPOSITIONS OF METFORMIN - The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions. | 2020-10-08 |
20200315995 | STERILIZED CHLORHEXIDINE ARTICLE AND METHOD OF STERILIZING A CHLORHEXIDINE ARTICLE - A sterilized chlorhexidine product for topical disinfection includes a package and at least one sterilized chlorhexidine article comprising a cloth. The package includes a film defining an interior volume and the sterilized chlorhexidine article disposed within the interior volume. The package further includes a first sealed end portion positioned at a first end of the film and a second sealed end portion positioned at a second end of the film, wherein the first sealed end portion and the second sealed end portion define a hermetically sealed portion about the interior volume. | 2020-10-08 |
20200315996 | Treatment of Endometriosis and Niclosamide Derivatives - Niclosamide is an effective therapeutic medicament for the treatment of endometriosis. Niclosamide treatment can reduce the size of endometriotic lesions and reduce cell proliferation in the lesions. Niclosamide treatment can result in the inhibition of proteins and genes associated with inflammatory signaling, including those associated with NFκB and STAT3 activation, but without altering the expression of steroid hormone receptors. Niclosamide can be effective in reducing the growth of endometriotic lesions in female mice without impairing their ability to become pregnant and without negative effect on gestation and offspring. The invention herein is useful in treating symptoms associated with endometriosis, such as reducing the growth of lesions of the endometrium, without disrupting normal reproductive function in females. The invention also relates to derivatives of niclosamide having improved solubility and enhanced efficacy. | 2020-10-08 |
20200315997 | C5 Ketone Compositions, and Related Methods, for Therapeutic and Performance Supplementation - The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones. | 2020-10-08 |
20200315998 | COMPOSITION FOR IMPROVING INTESTINAL BARRIER FUNCTION - An object of the present invention is to provide: a composition for improving intestinal barrier function capable of improving intestinal barrier function; and an agent for enhancing the intestinal barrier function improvement action of gallic acid. The present invention relates to a composition for improving intestinal barrier function, containing: gallic acid as an active ingredient. | 2020-10-08 |
20200315999 | TEAT DIP WITH RESIDUAL EFFICACY - A germicidal composition comprising at least one fast-acting germicidal agent and at least one slow-acting germicidal agent is provided. The use of a dual germicide system permits the composition to provide an immediate antimicrobial effect when applied to an animal's skin, particularly, a bovine teat, and a residual antimicrobial effect for several hours after application. A method for testing this residual antimicrobial effect is also provided. | 2020-10-08 |
20200316000 | COMPOSITIONS AND METHODS FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATION - Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation. | 2020-10-08 |
20200316001 | COMPOSITION FOR TREATING ATOPY OR PRURITUS CONTAINING N-ACETYL OR N-ACYLAMINO ACID - The present disclosure relates to a composition for preventing, alleviating or treating pruritus and/or atopy using an N-acetylamino acid or an N-acylamino acid having almost no side effects on the human body. Also, the present disclosure relates to a cosmetic composition for moisturizing skin or soothing skin. The composition of the present disclosure may be utilized to ameliorate a problematic skin condition caused by various causes, or to safely and effectively alleviate or treat pruritus and/or atopy without concern about side effects. | 2020-10-08 |
20200316003 | Fudosteine Solution Preparation for Aerosol Inhalation, and Preparation Method Therefor - Disclosed are a fudosteine solution preparation for aerosol inhalation, and a preparation method therefor. The fudosteine solution preparation for aerosol inhalation comprises fudosteine, salts thereof and/or hydrates thereof; a metal complexing agent; and water for injection. The method for preparing the fudosteine solution preparation for aerosol inhalation includes the following steps: adding water for injection to a liquid formulation device and filling in nitrogen for protection, keeping the nitrogen in a liquid formulation tank at a positive pressure, and determining a residual oxygen content to be less than 2 mg/L; weighing the metal complexing agent, and stirring until the same dissolves; adding fudosteine, salts thereof and/or hydrates thereof, and stirring until the same dissolves; adding a pH adjusting agent, and determining the residual oxygen content to be less than 2 mg/L; supplementing with water for injection to a full amount, and stirring until evenly mixed; and carrying out fine filtration under sterile conditions, encapsulating and filling in nitrogen. | 2020-10-08 |
20200316004 | SPORTS HEALTH PERFORMANCE COMPOSITION - A topical composition that includes L-arginine that is used as a sports health composition. The composition can further include forskolin. Disclosed is a method of using the topical composition. | 2020-10-08 |
20200316005 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ACNE - The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom. | 2020-10-08 |
20200316006 | Methods of Reducing Apolipoprotein C-III - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2020-10-08 |
20200316007 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, COMPOSITIONS, METHODS AND USES THEREOF - There are provided various compositions comprising monoglyceride(s), diglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject. | 2020-10-08 |
20200316008 | BIOFILM INHIBITING COMPOSITIONS ENHANCING WEIGHT GAIN IN LIVESTOCK - A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or α-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided. | 2020-10-08 |
20200316009 | MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND Rho-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE INHIBITOR - Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug. | 2020-10-08 |
20200316010 | SILICA NANOPARTICLE WITH AN INSOLUBLE DRUG - Disclosed herein, inter alia, are nanoparticle compositions (e.g., silica nanoparticles) including insoluble drug nanocrystals and methods of using the same for treating cancer. | 2020-10-08 |
20200316011 | Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy - This disclosure relates to inhibitors of Mcl-1 stimulated homologous recombination (HR) DNA repair and uses for treating cancer. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an inhibitor of Mcl-1 in combination with other anti-cancer agents, e.g., that induce DNA replication stress. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering compounds disclosed herein in combination with hydroxyurea, olaparib, or combinations thereof. | 2020-10-08 |
20200316012 | Powdered Composition Comprising A Complex Between A Cannabinoid And A Basic Ion Exchange Resin - A powdered composition is disclosed, the powdered composition comprising a complex between one or more cannabinoids having at least one phenolic moiety and a basic ion exchange resin. Also, an orally dispensable delivery vehicle, a method of manufacturing the powdered composition, a method of manufacturing the orally dispensable delivery vehicle, composition for use as a medicament, composition for use in a treatment, method of treatment, and use of a basic ion exchange resin as a stabilizing agent are disclosed. | 2020-10-08 |
20200316013 | BRAIN HEALTH FORMULATION - The invention relates to a unique formulation for brain health. The formulation includes a mixture of CBD and THC and/or flavonoids, along with at least one antioxidant, and preferably an emulsifier, spearmint extract and a film-forming agent. The formulation improves memory and cognition as well as prevents and improves symptoms in dementia and related diseases related to deterioration or loss of memory and/or cognition. | 2020-10-08 |
20200316014 | Cannabinoid Compositions - A cannabinoid composition including a cannabinoid oil, such as THC oil or CBD oil, one or more thickeners such as gums, and a compound that forms an inclusion complex with the cannabinoid oil. The composition may include water, and in intermediate stages can include an alcohol. The composition can also include a sweetener to make it a sugar or a syrup. In some embodiments there are no other oils in the composition. | 2020-10-08 |
20200316015 | TERPENE-BASED COMPOSITIONS, METHODS OF PREPARATIONS AND USES THEREOF - The present disclosure generally relates to terpene-based compositions for applications in the pharmaceutical and recreational fields. In some embodiments, the compositions are enriched compositions or non-naturally occurring compositions which contain defined concentrations of one or more | 2020-10-08 |
20200316016 | COMPOSITIONS AND METHODS RELATED TO CANNABINOIDS, TERPENOIDS AND ESSENTIAL OILS - The present invention provides cannabinoid and terpenoid compositions, among others, and methods of use including as medicines, supplements and nutraceuticals. | 2020-10-08 |
20200316017 | A COMPOSITION FOR PREVENTING OR MITIGATING DEMENTIA - The present invention provides a composition for preventing or mitigating dementia in a subject comprising a mixture of tocotrienols, tocopherol, squalene and B vitamin, and a pharmaceutically acceptable carrier. | 2020-10-08 |
20200316018 | ANTIOXIDATIVE STRESS COMPOSITIONS, METHODS OF PREPARING AND USES THEREOF - Antioxidative stress compositions, methods of using antioxidative stress composition and methods of preparing antioxidative stress composition compositions are described. The antioxidative stress compositions may be chemopreventive and/or immunomodulatory. Resveratrol, genistein, ellagic acid, curcumin and quercetin may be included in the antioxidative stress composition compositions individually or in any combination. | 2020-10-08 |
20200316019 | METHOD FOR TREATING PROTEIN AGGREGATION DISEASES - The present invention provides a method for treating a protein aggregation disease, including: administering a pharmaceutical composition comprising a compound represented by the following formula (I) to a subject in need thereof, | 2020-10-08 |
20200316020 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASES CONTAINING FLUOXETINE AND VITAMIN C AS ACTIVE INGREDIENTS - The present invention relates to a pharmaceutical composition for the prevention and treatment of blood-brain barrier disorder and central nervous system diseases containing fluoxetine and vitamin C as active ingredients. Specifically, when low concentration of fluoxetine and vitamin C, which did not show any improved effect on the blood-brain barrier disorder and disruption of blood-spinal cord barrier when administered alone, were mixed and co-administered to an animal model with spinal cord injury and transient global ischemia, the co-administration significantly increased the effect of inhibiting the increase of permeability of blood-spinal cord barrier and the effect of inhibiting MMP-9 activation and the effect of alleviating the influx of blood cells in an animal model with spinal cord injury; and the effect of inhibiting the disruption of blood-brain barrier and the effect of recovering memory in a transient global ischemia animal model, compared to the single administration of fluoxetine or vitamin C at the same concentration. The results indicate the synergy effect and the decrease of side effects by the co-administration of the compound at a low concentration, and thus fluoxetine and vitamin C of the present invention can be effectively used as active ingredients for a pharmaceutical composition for the prevention and treatment blood-brain barrier disorder and central nervous system diseases. | 2020-10-08 |
20200316021 | Dosing Regimen of Siponimod - The present disclosure relates to a novel dosing regimen for the administration of siponimod or pharmaceutically acceptable co-crystals or salts thereof, in the treatment of stroke, in particular ischemic stroke, e.g. acute ischemic stroke. | 2020-10-08 |
20200316022 | STABILIZED STATIN FORMULATIONS - The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same. | 2020-10-08 |
20200316023 | Method Of Producing Bacterially Derived Indole-3-Propionic Acid And Compositions Comprising Same - Described herein is a method for producing indole-3-propionic acid and other indole derivatives via bacterial fermentation and compositions of the same. The method comprises adding bacteria having a nucleic acid sequence with at least 80% homology to the nucleic acid sequence of SEQ ID NO: 1 to a liquid fermentation medium; fermenting at about 36° C. under anaerobic conditions; adding a dehydrating agent; and dehydrating to obtain a fermentate powder comprising indole-3-propionic acid and other indole derivatives. | 2020-10-08 |
20200316024 | SULCARDINE SALTS - Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided. | 2020-10-08 |
20200316025 | STABLE AMORPHOUS ELIGLUSTAT PREMIX AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to pharmaceutical compositions of Eliglustat. In particular the present invention relates to stable amorphous Eliglustat premix having enhanced stability and dissolution properties. The present invention also provide a stable premix composition comprising amorphous Eliglustat or a pharmaceutical acceptable salt thereof, pharmaceutical compositions comprising the premixes, and processes for preparing the same. The compositions prepared in the present invention includes sublingual or mouth dissolving tablets, and capsules of Eliglustat and/or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier. | 2020-10-08 |
20200316026 | METHODS AND COMPOSITIONS OF ANTI-INFLAMMATORY DRUG AND DICER ACTIVATOR FOR TREATMENT OF NEURONAL DISEASES - The present invention discloses compositions, means and kits thereof for treating neuronal clinical indications in a mammalian subject. The composition comprises, inter alia, a synergistic combination of an anti-inflammatory drug and a DICER activator. The present invention further discloses methods for treating neuronal diseases including Motor neuron diseases (MNDs), ALS, FTD (Frontotemporal Dementia), macular degeneration (AMD) autism, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. | 2020-10-08 |
20200316027 | CANCER STEM CELL INHIBITOR - The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient. | 2020-10-08 |
20200316028 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE - Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes. | 2020-10-08 |
20200316029 | FIXED DOSE COMBINATION OF TELMISARTAN, HYDROCHLOROTHIAZIDE AND AMLODIPINE - The present invention discloses a pharmaceutical tablet with a first layer comprising telmisartan, and a second layer comprising hydrochlorothiazide, amiodipine, mannitol, microcrystalline cellulose and corn starch, and a method of producing such a tablet. | 2020-10-08 |
20200316030 | PHARMACEUTICAL COMPOUNDS - Benzimidazole derivatives of formula (I): (Formula (I)) wherein: R | 2020-10-08 |
20200316031 | METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES - The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases. | 2020-10-08 |
20200316032 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING RETINAL PIGMENT EPITHELIUM DEGENERATION AND METHODS USING THE SAME - There are provided inter alia compounds capable of inhibiting retinal pigment epithelium (RPE) degeneration or geography atrophy (GA) associated with age-related macular degeneration (AMD), and methods of using the same. | 2020-10-08 |
20200316033 | DOSING REGIMENS FOR THE TREATMENT OF FUNGAL INFECTIONS - Described herein are dosing regimens for the treatment of fungal infections such as onychomycosis using ravuconazole or a salt, solvate or prodrug thereof. | 2020-10-08 |
20200316034 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE - Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions. | 2020-10-08 |
20200316035 | THERAPEUTIC HETEROCYCLIC COMPOUNDS - Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed: | 2020-10-08 |
20200316036 | RING-FUSED THIAZOLINO 2-PYRIDONES IN COMBINATION WITH A DRUG AGAINST TUBERCULOSIS - Described is a composition that includes:
| 2020-10-08 |
20200316037 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA - The invention relates to unique compositions and methods for treating neoplasia. Specifically, the invention relates to an off-label combinatorial therapy that modulates angiogenesis and immune response to treat neoplasia. | 2020-10-08 |
20200316038 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS, IN PARTICULAR OTC DEFICIENCY - The present invention provides methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks. | 2020-10-08 |
20200316039 | Compositions and Methods of Enhancing the Homing and/or Engraftment of Hematopoietic Cells in the Central Nervous System - The present disclosure relates to compositions and methods for enhanced engraftment of hematopoietic cells into the brain, and to therapeutic methods of treating central nervous system (CNS) diseases and disorders in subjects where replacing CNS pot macrophages (including microglia) and other tissue-resident macrophages with donor cells would be beneficial. In particular, the present disclosure relates to the use of a microglia depleting agent to enhance engraftment of hematopoietic-derived macrophages in the brain of a subject undergoing hematopoietic cell transplantation, to treat a subject suffering from a leukodystrophy and undergoing hematopoietic cell transplantation, to treat a subject suffering from a disease mediated by microglial dysfunction and undergoing hematopoietic cell transplantation, and to related methods. The present disclosure also relates to detection within cell populations of beMcϕ and microglia signatures. | 2020-10-08 |
20200316040 | Bis-amines, Compositions, and Uses Related to CXCR4 Inhibition - This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula I, | 2020-10-08 |
20200316041 | FORMULATIONS OF AN LSD1 INHIBITOR - The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer. | 2020-10-08 |
20200316042 | FEXOFENADINE MICROCAPSULES AND COMPOSITIONS CONTAINING THEM - The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable drug content and desirable pharmaceutical properties, including a quick dissolution rate of fexofenadine combined with a taste masking effect. | 2020-10-08 |
20200316043 | PHARMACEUTICAL COMPOSITION COMPRISING CLEVIDIPINE AND PROCESS FOR PREPARATION THEREOF - The present invention relates to injectable oil in water pharmaceutical composition comprising effective amount of clevidipine or a pharmaceutically acceptable salt or ester as an active agent and process of preparation thereof. The invention also relates to the use of the emulsion in intravenous administration during surgery and postoperatively in hypertension and for short term treatment of hypertension when oral therapy is not feasible or desirable. | 2020-10-08 |
20200316044 | Personal Care Compositions - Described herein are complexes comprising a cationic antibacterial agent and a metal salt, personal care compositions comprising same; along with methods of making and using these complexes and compositions. | 2020-10-08 |
20200316045 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF - The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases. | 2020-10-08 |
20200316046 | NANOPARTICLE COMPOSITIONS OF ENDOTHELIN B RECEPTOR ANTAGONISTS - The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain. | 2020-10-08 |
20200316047 | CRYSTALLINE FORM OF A 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND - The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases. | 2020-10-08 |
20200316048 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS - The invention relates to compounds of formula I: | 2020-10-08 |
20200316049 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS - The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain. | 2020-10-08 |
20200316050 | A TOPICAL COMPOSITION BASED ON NIACINAMIDE DERIVATIVE - The present invention relates to a topical composition comprising a compound pf formula (I) wherein R is a cycloalkyl group with the total number of carbon atoms in the cycloalkyl group in the range 4 to 6. | 2020-10-08 |
20200316051 | TLR7/8 ANTAGONISTS AND USES THEREOF - A treatment of disorders related to TLR7/8 overexpression or aberrant activation is provided. The disorder may include multiple sclerosis, Alzheimer's Disease, myositis, stroke, ischemia, CNS neuropathies, systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, Guillain-Barré syndrome, alcoholic hepatitis, non-alcoholic steatohepatitis, congenital heart block, autoimmune hepatitis, autoimmune pancreatitis, adult onset Still's disease, drug-induced neurological disorders, and substance addiction. A compound of Formula (I) is useful to treat such disorders. | 2020-10-08 |
20200316052 | OPHTHALMIC COMPOSITION - Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthamic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein. | 2020-10-08 |
20200316053 | APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA AND CHONDROSARCOMA - The present disclosure relates to a new use of anlotinib, and relates in particular to anlotinib inhibiting osteosarcoma and chondrosarcoma growth and metastasis. It has been discovered for the first time that anlotinib can inhibit osteosarcoma and chondrosarcoma growth and metastasis. Anlotinib can significantly inhibit the growth of the osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, induce cycle arrest in said cell lines, and can also inhibit osteosarcoma cell line migration and invasion. It has also been discovered for the first time that anlotinib can enhance the killing effect of the chemotherapeutic drug cisplatin on osteosarcoma cells. | 2020-10-08 |
20200316054 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2020-10-08 |
20200316055 | TRANSDERMAL DELIVERY SYSTEM - The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising
| 2020-10-08 |
20200316056 | Pain Medicine Combination and Uses Thereof - Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia. | 2020-10-08 |
20200316059 | METHODS OF TREATING OR PREVENTING ZIKA VIRUS INFECTION - This document relates to methods and materials for treating a mammal having a Zika virus (ZIKV) infection. For example, a composition including one or more non-nucleoside RNA polymerase inhibitors can be administered to a mammal having, or at risk of developing, a ZIKV infection to treat the mammal | 2020-10-08 |
20200316060 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PAIN - The present invention relates to a pharmaceutical composition comprising a combination of trazodone or a salt thereof, and gabapentin or a salt or prodrug thereof, said combination having a synergistic effect in the treatment of pain. | 2020-10-08 |
20200316061 | ARIPIPRAZOLE PRODRUG COMPOSITION - Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (h) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition. | 2020-10-08 |
20200316062 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS - The invention relates to a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of proteasome inhibitors, tumour immunotherapeutics or immunomodulatory agents, signal transduction pathway inhibitors, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors. | 2020-10-08 |
20200316063 | COMPOUNDS AND METHODS FOR REGULATING, LIMITING, OR INHIBITING AVIL EXPRESSION - In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dys-regulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. | 2020-10-08 |
20200316064 | CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF - Biomarkers are provided that are predictive and/or indicative of a subject's responsiveness to a cyclin-dependent kinase 2 (CDK2) inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing a disease or disorder associated with CDK2 and for monitoring treatment. | 2020-10-08 |
20200316065 | sGC STIMULATORS - Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. | 2020-10-08 |
20200316066 | KILLING SENESCENT CELLS AND TREATING SENESCENCE-ASSOCIATED CONDITIONS USING A SRC INHIBITOR AND A FLAVONOID - Provided herein are methods and uses for treatment or prophylaxis of a senescent cell associated disease or disorder by administering a senolytic combination comprising dasatinib and quercetin or an analog thereof to a subject in need thereof. In certain embodiments, the senescent cell associated disease or disorder is a cardiovascular disease or disorder, inflanunatory disease or disorder, a pulmonary disease or disorder, a neurological disease or disorder, or a metabolic disease or disorder. | 2020-10-08 |
20200316067 | COMBINATION OF RAF INHIBITORS AND TAXANES - The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer. | 2020-10-08 |
20200316068 | Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity - The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK). | 2020-10-08 |
20200316069 | CYTOSINE-BASED TET ENZYME INHIBITORS - Provided herein, in some embodiments, are cytosine analogs, compositions comprising cytosine analogs, and methods of use for inhibiting a Ten-eleven translocation (TET) enzyme. | 2020-10-08 |
20200316070 | COMPOSITIONS AND METHODS FOR INHIBITING PTPN22 - The present invention provides compositions and methods for inhibiting PTPN22 for restoring human central B-cell tolerance or for treating or preventing an autoimmune disease or disorder. | 2020-10-08 |
20200316071 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONS - The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib. | 2020-10-08 |
20200316072 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION - The present invention relates to a compounds and methods for regulating follicle maturation, and the use thereof in treating, preventing or ameliorating an ovulation disorder and methods for treating females having an ovulation disorder. | 2020-10-08 |
20200316073 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION - Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient. | 2020-10-08 |
20200316074 | TARGETING ADENOSINE A2A RECEPTORS FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIAS - Provided herein are compositions and methods for the treatment and of neurodegenerative disorders and levodopa-induced dyskinesias. In particular, A2a receptor antagonists are provided, as well as methods for the use of A2a receptor antagonists in the treatment of neurodegenerative disorders (e.g., Parkinsons disease) and the treatment and/or prevention levodopa-induced dyskinesias associated with such treatment. | 2020-10-08 |
20200316075 | GANCICLOVIR COMPOSITIONS AND RELATED METHODS - Gancyclovir formulations that are ready-to-use, substantially particulate free, and stable upon storage are disclosed. Methods of manufacture and administration of such compositions are also provided. | 2020-10-08 |
20200316076 | Nucleotide Analogs - Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection. | 2020-10-08 |
20200316077 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER - The present disclosure discloses a pharmaceutical composition comprising compound of Formula I, Formula II, Formula III, Formula IV, and their pharmaceutically acceptable salts, analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, metabolites, and prodrugs thereof, for the manufacture of a medicament for the treatment of a condition or disorder ameliorated by inhibition of the A | 2020-10-08 |
20200316078 | METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION - The present invention provides a method for treating or preventing heart failure with preserved ejection fraction (HFPEF), wherein the method comprises administering to a patient having or at risk of developing HFPEF a therapeutically effective amount of imeglimin. | 2020-10-08 |
20200316079 | ERBB/BTK INHIBITORS - Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer. | 2020-10-08 |
20200316080 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES - Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases. | 2020-10-08 |
20200316081 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE - The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments. | 2020-10-08 |
20200316082 | DIHYDROOXADIAZINE COMPOUNDS FOR TREATING INFECTIONS AND CANCER - The invention relates to the use of 1-(4,6-dipentyl-5,6-dihydro-2H-1,2,3-oxadiazin-2-yl)-3-hydroxypropan-1-one in treating and/or preventing infections caused by a bacterium, fungus or virus or in treating and/or preventing cancer. Additionally, the invention relates to a process for obtaining the compound of formula (I) of the invention, said process comprising the steps of cultivating a strain of | 2020-10-08 |
20200316083 | ANTIBACTERIAL COMPOSITIONS - Pharmaceutical composition comprising beta-lactamase inhibitors or a pharmaceutically acceptable salt, and a compound of Formula (I) or a pharmaceutically acceptable salt thereof are disclosed. | 2020-10-08 |
20200316084 | METHODS TO TARGET TRANSCRIPTIONAL CONTROL AT SUPER-ENHANCER REGIONS - Methods for targeting super enhancers by administration of two or more therapeutic agents are provided. The methods are useful for treatment of various super-enhancer-mediated diseases and conditions, such as cancer. Compositions comprising the two or more therapeutic agents are also provided. | 2020-10-08 |
20200316086 | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS, 17-HDHA AND 18-HEPE AND METHODS OF USING SAME - The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same. | 2020-10-08 |